Zacks Research Forecasts Alkermes' Q4 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS - Free Report) - Equities researchers at Zacks Research increased their Q4 2025 earnings per share estimates for Alkermes in a research report issued on Thursday, June 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.53 per share for the quarter, up from their prior estimate of $0.51. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' Q2 2026 earnings at $0.54 EPS, Q4 2026 earnings at $0.57 EPS and FY2026 earnings at $1.93 EPS.

Several other equities research analysts also recently commented on ALKS. Needham & Company LLC began coverage on Alkermes in a report on Wednesday, May 28th. They set a "buy" rating and a $45.00 price objective for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. Robert W. Baird boosted their price objective on Alkermes from $38.00 to $41.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. HC Wainwright restated a "neutral" rating on shares of Alkermes in a report on Friday, May 2nd. Finally, Wall Street Zen downgraded Alkermes from a "strong-buy" rating to a "buy" rating in a report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Alkermes presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.

Alkermes Stock Performance

Shares of NASDAQ ALKS traded down $0.07 during midday trading on Monday, hitting $28.83. 1,799,974 shares of the stock traded hands, compared to its average volume of 1,725,854. The company has a market cap of $4.75 billion, a PE ratio of 13.79, a P/E/G ratio of 1.80 and a beta of 0.47. Alkermes has a one year low of $22.90 and a one year high of $36.45. The business has a 50 day moving average price of $29.91 and a two-hundred day moving average price of $30.98.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). The business had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The company's revenue for the quarter was down 12.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.43 earnings per share.

Insider Activity at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president now owns 86,208 shares of the company's stock, valued at approximately $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP boosted its position in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock worth $217,363,000 after purchasing an additional 903,802 shares during the last quarter. Renaissance Technologies LLC boosted its position in Alkermes by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock worth $157,568,000 after purchasing an additional 57,697 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Alkermes by 488.6% in the first quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company's stock worth $172,860,000 after purchasing an additional 4,345,523 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Alkermes by 7.2% in the first quarter. Baker BROS. Advisors LP now owns 4,483,285 shares of the company's stock worth $148,038,000 after purchasing an additional 301,534 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Alkermes by 0.4% in the first quarter. American Century Companies Inc. now owns 3,465,674 shares of the company's stock worth $114,437,000 after purchasing an additional 14,967 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.